Novel biologics platform for targeting tumors driven by intracellular oncoproteins
Novel biologics platform for targeting tumors driven by intracellular oncoproteins
批准号:
10356663
负责人:
SHOHEI KOIDE
金额:
$19.81万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-12-01 至 2023-11-30
关键词:
AddressAllelesAntibodiesAntineoplastic AgentsBindingBiological AssayBiological ProductsBiteCancer BiologyCell Surface ProteinsCell TherapyCell surfaceCellsClinicComplexDataDrug TargetingEffectivenessEffector CellElementsEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorEpitope spreadingExtracellular ProteinGoalsHaptensImmuneImmune checkpoint inhibitorImmunoglobulin GImmunotherapyIn VitroInterdisciplinary StudyLinkMHC Class I GenesMalignant NeoplasmsNatural Killer CellsOncogenesOncogenicOncoproteinsPeptide/MHC ComplexPeptidesPharmaceutical PreparationsPositioning AttributeProteinsResistanceSolid NeoplasmSurfaceTechnologyTestingTherapeuticTranslatingTumor Immunityantibody conjugateantibody engineeringbasecancer cellcancer therapycell killingchimeric antigen receptor T cellscovalent bonddrug discoveryefficacy evaluationexperimental studyimmunogenicityimprovedin vivoinhibitorinhibitor therapyinnovationmultidisciplinarymutantnew technologynovelpeptide drugprotein degradationrecruitresponsesmall molecule inhibitortargeted treatmenttumor
中文摘要
该项目的目标是建立一种新的平台技术,以解决
目前针对由细胞内癌蛋白驱动的肿瘤的方法。许多癌基因编码激活的
细胞内蛋白质的变体。虽然生物制剂正在彻底改变癌症治疗,但它们并不容易
进入细胞,因此对细胞内靶无效。细胞内蛋白质的片段是
这些细胞由细胞表面的MHC分子呈递,但识别健康人和正常人之间的差异是具有挑战性的。
蛋白质和它们的致癌对应物通常是微小的。已经开发了许多共价抑制剂
针对细胞内癌蛋白,但大多数,像其他靶向治疗,引起耐药性,
实现癌症治愈。相比之下,“免疫疗法”(例如,免疫检查点抑制剂,CAR-T细胞)可以
是治愈性的,但大多数细胞内癌基因驱动的肿瘤未能响应这些药物。
我们提出了一个潜在的变革性创新,使用共价抑制剂联合靶向治疗
使用生物制剂进行免疫治疗。我们将开发“HapImmune”抗体,
与抑制剂共价连接并由MHC I类呈递于细胞表面的癌蛋白片段
癌细胞结合的抑制剂作为半抗原增加癌蛋白的免疫原性
片段药物和抗体的共同给药将通过参与免疫反应来启动癌细胞的杀伤。
攻击、抗原扩散和最终持久的抗肿瘤免疫。
令人信服的初步数据表明,HapImmune抗体可以产生针对几种
药物-肽缀合物。我们的多学科团队在癌症生物学、药物治疗和癌症治疗领域拥有互补的专业知识。
发现,抗体工程是很好的定位,以进一步发展和探索的适用性,
HapImmune概念用于改善靶向治疗。我们将实现以下两个目标:(1)我们将
开发结合共价药物AMG 510的抗体,AMG 510与KRASG 12 C肽结合,
MHC。尽管AMG 510有望彻底改变由KRASG 12 C驱动的癌症治疗,但其疗效
是短暂的我们将研究这种抗体在体外和体内选择性杀死癌症的功效
已经用AMG 510预处理的细胞。这些实验将批判性地评估
HapImmune方法使用癌症药物发现中的主要当前靶标。(2)我们将评估更广泛的
HapImmune方法的适用性,使用不同的靶点-药物对,使用EGFR的共价抑制剂
和BTK。我们将开发针对这些结合物的抗体,这些结合物存在于适当的MHC分子上,
它们在基于细胞的测定中的功效。这些实验应该提供一个严格的测试,
HapImmune方法的适用性和我们开发HapImmune抗体的能力。
如果成功,该项目将建立一个简单的管道,以产生潜在的变革性疗法
可以迅速转化为临床。
英文摘要
The goal of this project is to establish a new platform technology that addresses fundamental limitations of
current approaches against tumors driven by intracellular oncoproteins. Many oncogenes encode activated
versions of intracellular proteins. Although biologics are revolutionizing cancer therapy, they do not readily
enter cells and thus are ineffective against intracellular targets. Fragments of intracellular proteins are
presented by MHC molecules on cell surface, but it is challenging to recognize differences between healthy
proteins and their oncogenic counterparts that are often minute. Many covalent inhibitors have been developed
against intracellular oncoproteins, but most of them, like other targeted therapies, evoke resistance and fail to
achieve cancer cures. By contrast, “immune therapies” (e.g., immune checkpoint inhibitors, CAR-T cells) can
be curative, but most intracellular oncogene-driven tumors fail to respond to these agents.
We propose a potentially transformative innovation that unites targeted therapy using covalent inhibitors
with immune therapy using biologics. We will develop “HapImmune” antibodies that selectively recognize
fragments of an oncoprotein covalently linked to an inhibitor and presented by MHC Class I on the surface of
cancer cells. The conjugated inhibitor serves as a hapten that increases the immunogenicity of the oncoprotein
fragments. Co-administration of drug and antibody will initiate killing of cancer cells by engaging immune
attack, antigen spreading and ultimately durable anti-tumor immunity.
Compelling preliminary data demonstrate that HapImmune antibodies can be generated against several
drug-peptide conjugates. Our multi-disciplinary team with complementary expertise in cancer biology, drug
discovery, and antibody engineering is well positioned to further develop and explore the applicability of the
HapImmune concept for improving targeted therapy. We will execute the following two Aims: (1) We will
develop antibodies that bind a covalent drug, AMG510 conjugated with a KRASG12C peptide presented on an
MHC. Although AMG510 is expected to revolutionize therapy against cancers driven by KRASG12C, its efficacy
is short-lived. We will examine the efficacy of such antibodies in selective killing in vitro and in vivo of cancer
cells that have been pretreated with AMG510. These experiments will critically evaluate the impact of the
HapImmune approach using a major current target in cancer drug discovery. (2) We will assess the broader
applicability of the HapImmune approach using distinct target-drug pairs, using covalent inhibitors of EGFR
and BTK. We will develop antibodies to these conjugates presented on appropriate MHC molecules and test
their efficacy in cell-based assays. These experiments should provide a rigorous test of the general
applicability of the HapImmune approach and our ability to develop HapImmune antibodies.
If successful, this project will establish a facile pipeline to produce potentially transformative therapeutics
that can be rapidly translated into clinic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transport Mechanisms and Inhibition of Efflux Pumps in Pathogenic Organisms
-
批准号:10344321
-
项目类别:
-
资助金额:$74.35万
-
财政年份:2021
-
负责人:SHOHEI KOIDE
-
依托单位:
Novel biologics platform for targeting tumors driven by intracellular oncoproteins
-
批准号:10533364
-
项目类别:
-
资助金额:$23.3万
-
财政年份:2021
-
负责人:SHOHEI KOIDE
-
依托单位:
Transport Mechanisms and Inhibition of Efflux Pumps in Pathogenic Organisms
-
批准号:10531273
-
项目类别:
-
资助金额:$74.35万
-
财政年份:2021
-
负责人:SHOHEI KOIDE
-
依托单位:
Accurate prediction of neutralization capacity from deep mining of SARS-CoV-2 serology
-
批准号:10195613
-
项目类别:
-
资助金额:$46.61万
-
财政年份:2020
-
负责人:SHOHEI KOIDE
-
依托单位:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
-
批准号:9977135
-
项目类别:
-
资助金额:$55.1万
-
财政年份:2018
-
负责人:SHOHEI KOIDE
-
依托单位:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
-
批准号:10220892
-
项目类别:
-
资助金额:$55.1万
-
财政年份:2018
-
负责人:SHOHEI KOIDE
-
依托单位:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
-
批准号:9751810
-
项目类别:
-
资助金额:$53.45万
-
财政年份:2018
-
负责人:SHOHEI KOIDE
-
依托单位:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
-
批准号:9384266
-
项目类别:
-
资助金额:$17.99万
-
财政年份:2017
-
负责人:SHOHEI KOIDE
-
依托单位:
Probing RAS-mediated Signaling with Monobody Inhibitors
-
批准号:10530818
-
项目类别:
-
资助金额:$60.15万
-
财政年份:2017
-
负责人:SHOHEI KOIDE
-
依托单位:
Probing RAS-mediated Signaling with Monobody Inhibitors
-
批准号:10666670
-
项目类别:
-
资助金额:$57.7万
-
财政年份:2017
-
负责人:SHOHEI KOIDE
-
依托单位:
Molecular mechanisms of SHP2 signaling dissected with designer binding proteins
-
批准号:9889907
-
项目类别:
-
资助金额:$37.35万
-
财政年份:2016
-
负责人:SHOHEI KOIDE
-
依托单位:
Molecular mechanisms of SHP2 signaling dissected with designer binding proteins
-
批准号:9028914
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2016
-
负责人:SHOHEI KOIDE
-
依托单位:
Genetically encoded designer inhibitors for functional epigenomics
-
批准号:8858611
-
项目类别:
-
资助金额:$39.01万
-
财政年份:2013
-
负责人:SHOHEI KOIDE
-
依托单位:
Genetically encoded designer inhibitors for functional epigenomics
-
批准号:8642438
-
项目类别:
-
资助金额:$41.29万
-
财政年份:2013
-
负责人:SHOHEI KOIDE
-
依托单位:
SYNTHETIC BINDING PROTEINS
-
批准号:8361633
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2011
-
负责人:SHOHEI KOIDE
-
依托单位:
Core D3: Synthetic Antigen Binder Generation & Crystallography
-
批准号:7922836
-
项目类别:
-
资助金额:$50.97万
-
财政年份:2010
-
负责人:SHOHEI KOIDE
-
依托单位:
Renewable synthetic antibodies for epigenomics
-
批准号:7936835
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:SHOHEI KOIDE
-
依托单位:
Rational generation of directed protein-capture reagents
-
批准号:8539025
-
项目类别:
-
资助金额:$49.48万
-
财政年份:2009
-
负责人:SHOHEI KOIDE
-
依托单位:
Renewable synthetic antibodies for epigenomics
-
批准号:7815889
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:SHOHEI KOIDE
-
依托单位:
Rational generation of directed protein-capture reagents
-
批准号:7944024
-
项目类别:
-
资助金额:$50.3万
-
财政年份:2009
-
负责人:SHOHEI KOIDE
-
依托单位:
海外基金